Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy

Ahir, Manisha; Upadhyay, Priyanka; Ghosh, Avijit; Sarker, Sushmita; Bhattacharya, Saurav; Gupta, P. C. Sen; Ghosh, Swatilekha; Chattopadhyay, Sreya; Adhikary, Arghya

doi:10.1039/d0bm00015a

Cited by 68 publications

(36 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on these discovered molecular mechanisms, some progress has been made in breast cancer treatment. Delivering dual microRNA using CD44-targeted mesoporous silica nanoparticles proved to be effective in TNBC treatment [ 26 ]. Although many studies provided in vitro and in vivo a detailed molecular picture of TNBC cancers [ 27 – 29 ], the underlying cause of breast cancer has not been fully understood.…”

Section: Introductionmentioning

confidence: 99%

Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis

Wei

Zeng

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: The situation faced by breast cancer patients, especially those with triple-negative breast cancer, is still grave. More effective therapeutic targets are needed to optimize the clinical management of breast cancer. Although collagen type VIII alpha 1 chain (COL8A1) has been shown to be downregulated in BRIP1-knockdown breast cancer cells, its clinical role in breast cancer remains unknown. Methods: Gene microarrays and mRNA sequencing data were downloaded and integrated into larger matrices based on various platforms. Therefore, this is a multi-centered study, which contains 5048 breast cancer patients and 1161 controls. COL8A1 mRNA expression in breast cancer was compared between molecular subtypes. In-house immunohistochemistry staining was used to evaluate the protein expression of COL8A1 in breast cancer. A diagnostic test was performed to assess its clinical value. Furthermore, based on differentially expressed genes (DEGs) and coexpressed genes (CEGs) positively related to COL8A1, functional enrichment analyses were performed to explore the biological function and potential molecular mechanisms of COL8A1 underlying breast cancer. Results: COL8A1 expression was higher in breast cancer patients than in control samples (standardized mean difference = 0.79; 95% confidence interval [CI] 0.55-1.03). Elevated expression was detected in various molecular subtypes of breast cancer. An area under a summary receiver operating characteristic curve of 0.80 (95% CI 0.76-0.83) with sensitivity of 0.77 (95% CI 0.69-0.83) and specificity of 0.70 (95% CI 0.61-0.78) showed moderate capacity of COL8A1 in distinguishing breast cancer patients from control samples. Worse overall survival was found in the higher than in the lower COL8A1 expression groups. Intersected DEGs and CEGs positively related to COL8A1 were significantly clustered in the proteoglycans in cancer and ECM-receptor interaction pathways. Conclusions: Elevated COL8A1 may promote the migration of breast cancer by mediating the ECM-receptor interaction and synergistically interplaying with DEGs and its positively related CEGs independently of molecular subtypes. Several genes clustered in the proteoglycans in cancer pathway are potential targets for developing effective agents for triple-negative breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis

Wei

Zeng

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…MSNs have also shown promising efficacy in photodynamic therapy, an alternative to radio-and chemotherapies [107,108]. In this approach, the photosensitizers are incorporated into MSNs, while functionalizing them with specific ligands to target cancer cells [97,105,109].…”

Section: Functionalizationmentioning

confidence: 99%

An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine

et al. 2021

View full text Add to dashboard Cite

The efficient and safe delivery of therapeutic drugs, proteins, and nucleic acids are essential for meaningful therapeutic benefits. The field of nanomedicine shows promising implications in the development of therapeutics by delivering diagnostic and therapeutic compounds. Nanomedicine development has led to significant advances in the design and engineering of nanocarrier systems with supra-molecular structures. Smart mesoporous silica nanoparticles (MSNs), with excellent biocompatibility, tunable physicochemical properties, and site-specific functionalization, offer efficient and high loading capacity as well as robust and targeted delivery of a variety of payloads in a controlled fashion. Such unique nanocarriers should have great potential for challenging biomedical applications, such as tissue engineering, bioimaging techniques, stem cell research, and cancer therapies. However, in vivo applications of these nanocarriers should be further validated before clinical translation. To this end, this review begins with a brief introduction of MSNs properties, targeted drug delivery, and controlled release with a particular emphasis on their most recent diagnostic and therapeutic applications.

show abstract

“…Similar approaches have been developed for other cancer types, such as triple negative breast cancer (TNBC), where miR-34a is down-regulated and miR-10b is up-regulated. By co-delivering miR-34a-mimic and antisense-miR-10b in MSNs, Ahir et al achieved the efficient inhibition of tumor growth and the retardation of metastasis in an in vivo model of TNBC [ 104 ].…”

Section: Mesoporous Silica Nanoparticles For Gene Deliverymentioning

confidence: 99%

Mesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review

Paris

Vallet‐Regí

2020

Pharmaceutics

View full text Add to dashboard Cite

Mesoporous silica nanoparticles have attracted much attention in recent years as drug and gene delivery systems for biomedical applications. Among their most beneficial features for biomedicine, we can highlight their biocompatibility and their outstanding textural properties, which provide a great loading capacity for many types of cargos. In the context of cancer nanomedicine, combination therapy and gene transfection/silencing have recently been highlighted as two of its most promising fields. In this review, we aim to provide an overview of the different small molecule drug-nucleic acid co-delivery combinations that have been developed using mesoporous silica nanoparticles as carriers. By carefully selecting the chemotherapeutic drug and nucleic acid cargos to be co-delivered by mesoporous silica nanoparticles, different therapeutic goals can be achieved by overcoming resistance mechanisms, combining different cytotoxic mechanisms, or providing an additional antiangiogenic effect. The examples here presented highlight the great promise of this type of strategies for the development of future therapeutics.

show abstract

Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy

Abstract: Cationic Mesoporous silica Nanoparticle coated with hyaluronic acid conjugated polymer (HA-Dual miRNA Np) facilitated enhanced dual miRNA loading, efficient delivery and significantly inhibited tumor growth as well as retarded metastasis in triple-negative breast cancer.

Cited by 68 publications

References 44 publications

Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis

Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis

An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine

Mesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review

Contact Info

Product

Resources

About